)

MacroGenics (MGNX) investor relations material
MacroGenics H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Company overview and pipeline
Focuses on next-generation antibodies for cancer, with four clinical-stage programs across three modalities, including ADCs and multi-specific platforms.
Utilizes proprietary DART and Trident platforms for t cell engagers and bispecifics, with some assets partnered with major pharma companies.
Three molecules leverage the Cinefix ADC platform, with broad access due to early adoption and up to seven molecules possible.
Portfolio includes both proprietary and partnered programs, with several approved and commercialized molecules.
Cash and marketable securities total $177M, with a runway through 2027, bolstered by a $70M royalty monetization deal.
Key clinical programs and data
Lorigirlimab, a PD-1/CTLA-4 bispecific, is in phase 1 for prostate and gynecologic cancers, showing a 26% ORR and 29% PSA response in late-line prostate cancer.
Durability of response is notable, with some patients maintaining benefit for up to two years.
Safety profile shows fewer severe immune-mediated events compared to traditional CTLA-4 agents, with only 1-2 grade 3 colitis cases in 120+ patients.
Lorikeet study (prostate cancer) is fully enrolled, with a clinical update expected later this year; Lannett study (gynecologic cancers) is ongoing.
ADC programs target B7-H3, ADAM9, and an undisclosed target, with phase 1 studies ongoing and IND submission for O30 planned next year.
Technology and competitive positioning
Cinefix ADC platform enables site-specific conjugation and potent exoticon payload, offering higher potency and less susceptibility to resistance.
Proprietary HydraSpace technology allows conjugation to hydrophobic payloads, improving drug characteristics.
Internal data show strong in vivo efficacy and efficient internalization compared to competitors.
Market validation for the Cinefix linker from other pharma alliances and phase 3 advancement by Innovent.
ADC targets have broad expression across solid tumors, with competitive but non-exclusive market dynamics.
Next MacroGenics earnings date

Next MacroGenics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage